Log in

ASX:RCERecce Pharmaceuticals Stock Price, Forecast & News

-0.01 (-2.06 %)
(As of 05/12/2020)
Today's Range
Now: A$0.48
50-Day Range
MA: A$0.48
52-Week Range
Now: A$0.48
Volume630,087 shs
Average VolumeN/A
Market Capitalization$64.40 million
P/E RatioN/A
Dividend YieldN/A
Recce Pharmaceuticals Ltd, a biotechnology company, researches and develops antibiotic drugs in Australia. The company focuses on the development of RECCE 327 that helps to address the problem of antibiotic resistant superbugs. It also develops drugs for the treatment of stomach ulcers and diarrhea. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Phone61 2 8075 4585



Sales & Book Value

Annual Sales$1.07 million
Cash FlowA$0.04 per share
Book ValueA$0.04 per share



Market Cap$64.40 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RCE News and Ratings via Email

Sign-up to receive the latest news and ratings for RCE and its competitors with MarketBeat's FREE daily newsletter.

Recce Pharmaceuticals (ASX:RCE) Frequently Asked Questions

How has Recce Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Recce Pharmaceuticals' stock was trading at A$0.33 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RCE shares have increased by 46.2% and is now trading at A$0.48. View which stocks have been most impacted by Coronavirus.

How were Recce Pharmaceuticals' earnings last quarter?

Recce Pharmaceuticals Ltd (ASX:RCE) announced its quarterly earnings data on Wednesday, February, 27th. The company reported ($0.01) earnings per share for the quarter. View Recce Pharmaceuticals' earnings history.

Has Recce Pharmaceuticals been receiving favorable news coverage?

Media stories about RCE stock have trended very negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Recce Pharmaceuticals earned a news impact score of -3.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Recce Pharmaceuticals.

Who are some of Recce Pharmaceuticals' key competitors?

What other stocks do shareholders of Recce Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Recce Pharmaceuticals investors own include FlexiGroup (FXL), ASE Technology (ASX), IMMUTEP LTD/S (IMMP), Mavenir Systems (MVNR), Micron Technology (MU), Seres Therapeutics (MCRB), Ilika (IKA), Turtle Beach (HEAR), Applied Optoelectronics (AAOI) and First Graphene (FGR).

Who are Recce Pharmaceuticals' key executives?

Recce Pharmaceuticals' management team includes the following people:
  • Dr. Graham John Hamilton Melrose BSc(Hons), Ph.D., MBA, FRACI, CChem, FAICD, Exec. Chairman & Chief Research Officer (Age 85)
  • Mr. James Hamilton-Bray Graham, Exec. Director and Exec. Director of Marketing & Bus. Devel.
  • Ms. Michele Dilizia, Exec. Director and Exec. Director of Regulatory Affairs & Microbiology
  • Dr. Justin Ward, Principal Quality Chemist
  • Mr. Justin Reynolds, Chief Financial Officer

What is Recce Pharmaceuticals' stock symbol?

Recce Pharmaceuticals trades on the ASX under the ticker symbol "RCE."

What is Recce Pharmaceuticals' stock price today?

One share of RCE stock can currently be purchased for approximately A$0.48.

How big of a company is Recce Pharmaceuticals?

Recce Pharmaceuticals has a market capitalization of $64.40 million and generates $1.07 million in revenue each year.

What is Recce Pharmaceuticals' official website?

The official website for Recce Pharmaceuticals is www.recce.com.au.

How can I contact Recce Pharmaceuticals?

The company can be reached via phone at 61 2 8075 4585.

This page was last updated on 7/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.